You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
The GLP-1 drama continues at Hims & Hers.
Hims & Hers (HIMS 1.01%) fell as much as 12% in trading on Wednesday after pharmaceutical company Novo Nordisk (NVO -2.99%) asked the FDA to not allow companies to compound GLP-1 semaglutide. This could be a direct hit to Hims & Hers business, but the impact may not be what you think, as Travis Hoium covers in this video.
*Stock prices used were end-of-day prices of Oct. 23, 2024. The video was published on Oct. 23, 2024.
Travis Hoium has positions in Hims & Hers Health. The Motley Fool recommends CVS Health and Novo Nordisk. The Motley Fool has a disclosure policy. Travis Hoium is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
